Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E17.26 EPS (ttm)2.23 Insider Own- Shs Outstand2.63B Perf Week-6.19%
Market Cap101.41B Forward P/E12.42 EPS next Y3.10 Insider Trans- Shs Float2.35B Perf Month-3.77%
Income5.90B PEG2.62 EPS next Q0.74 Inst Own9.80% Short Float0.10% Perf Quarter-15.29%
Sales41.50B P/S2.44 EPS this Y18.50% Inst Trans-3.00% Short Ratio1.27 Perf Half Y-29.23%
Book/sh23.44 P/B1.64 EPS next Y-1.74% ROA6.80% Target Price55.02 Perf Year-17.57%
Cash/sh1.94 P/C19.84 EPS next 5Y6.60% ROE11.80% 52W Range38.33 - 54.98 Perf YTD-9.75%
Dividend1.61 P/FCF- EPS past 5Y-4.00% ROI7.00% 52W High-29.99% Beta1.04
Dividend %4.18% Quick Ratio1.40 Sales past 5Y1.80% Gross Margin68.40% 52W Low0.42% ATR0.89
Employees113496 Current Ratio1.40 Sales Q/Q9.20% Oper. Margin23.10% RSI (14)34.92 Volatility1.55% 1.86%
OptionableYes Debt/Eq0.26 EPS Q/Q36.70% Profit Margin17.00% Rel Volume1.30 Prev Close38.87
ShortableYes LT Debt/Eq0.19 EarningsFeb 09 BMO Payout32.70% Avg Volume1.81M Price38.49
Recom2.30 SMA20-4.98% SMA50-8.00% SMA200-19.52% Volume2,254,100 Change-0.98%
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Feb-10-16 11:58AM  Sanofi -- Moody's: Europe's pharma companies' earnings growth looking less rosy in 2016 at Moody's
11:40AM  Sanofi Tops Q4 Earnings, Revenues Fall Y/Y, Gives 2016 View
12:52AM  [$$] How a Sanofi Diabetes Bet Went Wrong at The Wall Street Journal
Feb-09-16 06:22PM  Regeneron Q4 Earnings Miss Estimates Amid Slow Praluent Launch
04:06PM  [$$] Sanofi Is Forced to End Latest Diabetes Effort at The Wall Street Journal
12:04PM  Why MannKind Corporation Is Popping Today at Motley Fool
11:34AM  [$$] Sanofi upbeat on prospects for heart drug despite slow start in US at Financial Times
10:58AM  Pfizer Reported 7% Top Line Growth in 4Q15
10:50AM  Regeneron: Get Used to Disappointment at
09:45AM  Sanofi reports flat 2015 earnings
08:11AM  Sanofi's Stock Dips Lower Following Q4 Print
08:05AM  Sanofi Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at Constant Exchange Rates Consistent with Guidance PR Newswire
07:22AM  [$$] Regeneron Reports Slowing Sales Growth for Key Eye Drug at The Wall Street Journal
06:25AM  Sanofi Genzyme revenues grow 20% in 2015 to top $4B at
03:40AM  [$$] Sanofi Profit Hit By Falling Diabetes Revenue at The Wall Street Journal
02:12AM  Sanofi - Full Year 2015 Results PR Newswire
01:30AM  Sanofi Says 2016 Profit Won't Grow as Bestseller Lantus Fades at Bloomberg
12:33AM  Sanofi delivered 2015 business EPS up 8.5% on a reported basis and stable at constant exchange rates consistent with guidance ACN Newswire
Feb-08-16 06:36PM  Sanofi gets shot in the arm from dollar strength AFP
05:08PM  Why Novo Nordisk Fell after Its 4Q15 Earnings Release
11:30AM  Regeneron: It's the Eylea Outlook That Matters at
10:22AM  [$$] Obama asks Congress for $1.8bn to battle Zika virus at Financial Times
10:06AM  Can NewLink Genetics Win the Zika Vaccine Race? at Motley Fool
09:00AM  Why Sanofi (SNY) Might Surprise This Earnings Season
Feb-06-16 07:00AM  Trade Boost From Trans-Pacific Partnership?
Feb-05-16 05:16PM  3 Things to Look for in Regeneron Pharmaceuticals Inc.'s Earnings at Motley Fool
Feb-04-16 03:59PM  Is Inovio Pharmaceuticals' Zika Surge Premature? at Motley Fool
03:32PM  Frances Services Business Activity Returned to Marginal Growth
10:07AM  Expectations for Valeant Pharmaceuticals in 2016
08:07AM  Valeant Pharmaceuticals: The Near-Term Growth Prospects
08:00AM  Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Accesswire
Feb-03-16 04:20PM  Sanofi Begins Search for Vaccine for Zika Virus as Fear Grows
03:50PM  Will AmerisourceBergen's (ABC) Q1 Earnings Disappoint?
01:49PM  Frances Manufacturing Activity Stagnated in January
02:30AM  Moderate Improvements in Blood Glucose Levels Could Deliver Significant Benefits for People With Diabetes in the UK and the NHS PR Newswire
12:25AM  [$$] Drug Industry Starts Race to Develop Zika Vaccine at The Wall Street Journal
Feb-02-16 07:32PM  The Latest: Chile reports its first 3 confirmed Zika cases
05:40PM  Why Regeneron Pharmaceuticals Shares Fell 23% in January at Motley Fool
04:52PM  First U.S. Zika virus transmission reported, sexual transmission cited Reuters
02:50PM  Cambridge developer of cystic fibrosis drugs joins choppy IPO waters at
12:57PM  Video-Q3 2015 RESULTS for Sanofi at Company Spotlight
10:18AM  Merck, Sanofi Exploring Potential End To Joint Venture In Europe
10:12AM  [$$] Sanofi to Launch Zika Vaccine Research at The Wall Street Journal
09:07AM  Drugmaker Sanofi Pasteur launches effort for Zika vaccine
06:43AM  Sanofi Tells Unions Drugmaker Plans 600 Job Cuts in France at Bloomberg
03:17AM  Sanofi launches hunt for Zika vaccine as disease fears grow Reuters
02:47AM  Sanofi to Work on Zika Vaccine as Health Emergency Declared at Bloomberg
01:14AM  [$$] Sanofi leads hunt for vaccine to beat Zika at Financial Times
Feb-01-16 07:33PM  France's Sanofi launches Zika virus vaccine research AFP
07:08PM  Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
04:07PM  Novartis Reports Operational Growth in 4Q15
01:07PM  Can Consumer Healthcare Drive Sanofis Revenue?
07:05AM  Elanco Contributed ~15% of Total Revenues for Eli Lilly
Jan-31-16 02:18PM  3 Feverishly Bad Flu Myths That Should Be Put to Rest at Motley Fool
Jan-30-16 03:15PM  Chinas diabetes boom promises $23 billion pot for drug makers at MarketWatch
01:01PM  Biotech's Dumbest CEO Moves in 2015 at Motley Fool
Jan-29-16 04:39PM  Biotech Stocks Soar In Race To Create Zika Vaccine at Forbes
03:13PM  A Look at Prospects for Genzyme, a Sanofi Company
03:13PM  How Much Sales Growth Can We Expect from Sanofis 4Q15 Earnings?
03:13PM  What do Analysts Expect from Sanofis 4Q15 Earnings?
01:38PM  EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
03:04AM  Will GSKs Consumer Healthcare Sustain Growth during 4Q15?
Jan-28-16 12:18PM  Sanofi and the Iran Ministry of Health and Medical Education Sign a Memorandum of Cooperation at noodls
12:04PM  Insight into Tevas Over-the-Counter and Distribution Businesses
07:10AM  Sanofi Genzyme expanding in Westborough at
Jan-27-16 04:50PM  MannKind reportedly looking to sell itself at
04:50PM  Here's the Case for and Against a MannKind Acquisition at Motley Fool
11:45AM  Why MannKind Corporation's Shares Are Skyrocketing Today at Motley Fool
07:00AM  Report: Struggling drugmaker MannKind looking for a buyer at Los Angeles Times
Jan-26-16 02:52PM  Insulin drug maker Mannkind explores sale -sources
12:35PM  Why MannKind Corporation's Stock Is Up Today at Motley Fool
Jan-25-16 02:09PM  Glaxo evaluating possibility of using vaccine technology for Zika Reuters
12:46PM  Vertex Pharmaceuticals: What Are Analysts Estimates?
12:14PM  Zika virus set to spread across Americas, spurring vaccine hunt
09:51AM  Regeneron: Sell on Patent Fears, Chardan Says at
Jan-23-16 12:01AM  [$$] Sanofi's Pipeline to Robust Health at
Jan-22-16 03:20PM  MannKind (MNKD) Signs Deal with Receptor Life Sciences
01:04PM  Orange Topped FEZ in Preliminary Merger Talks with Bouygues
05:04AM  Frances Services Business Activity Stagnated in December 2015
Jan-21-16 12:52PM  MannKind Corporation Lands a New Deal -- Were Investors Right to Cheer? at Motley Fool
Jan-20-16 10:27AM  Sanofi Rose 3.5%, Disclosed a Deal Worth up to 1.2 Billion Euros
10:27AM  EON Is in Talks to Sell Its Stake in Turkeys Enerjisa
Jan-19-16 01:47PM  What Are the Potential Drivers of BioMarin?
01:47PM  What Are Analysts Expectations for BioMarin?
01:06PM  Stocks Struggle to Hold Gains as Energy Falls at TheStreet
10:07AM  How Will Sandoz Perform in Novartiss 4Q15 Earnings?
07:19AM  What If Medicare Had Teeth? at Motley Fool
Jan-18-16 02:06PM  How Is Novo Nordisks Position in the Diabetes Segment?
02:04PM  What to Expect from Novo Nordisks 4Q15 Earnings
Jan-15-16 06:00PM  Walgreens, CVS, Illumina, Jazz Top New Insider Trades at Investor's Business Daily
11:52AM  Can Twitter Save MannKind Corporation? at Motley Fool
Jan-14-16 03:37PM  MannKind Corporation Is Moving Higher Again -- Here's Why at Motley Fool
09:04AM  Why Keryx Biopharmaceuticals Dropped 64% in 2015 at Motley Fool
Jan-13-16 04:45PM  Roche's NDA for Lymphocytic Leukemia Drug Accepted by FDA
12:35PM  Why MannKind Corportion Is Soaring Today at Motley Fool
Jan-12-16 09:39AM  What Investors Can Learn from MannKind Corporation's Afrezza Fiasco at Motley Fool
Jan-11-16 04:40PM  Sanofi Inks Multiple Deals, Sarilumab under FDA Review
12:20PM  Sanofi Extends Warp Drive Development Deal for Five Years
09:48AM  7 Thoughts On Today's Pharma & Biotech News at Forbes
08:40AM  [$$] Sanofi unveils ?1.2bn of deals as part of push into cancer drugs at Financial Times
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM